HK Innoen 'K-Cab Tablets' Show Consecutive Sales Growth Trend

HK Innoen 'K-Cab Tablet' (Photo by HK Innoen)

[Asia Economy Reporter Chunhee Lee] HK Innoen's gastroesophageal reflux disease new drug 'K-CAB Tablet' is showing continuous sales growth.

According to the industry on the 16th, the prescription performance of K-CAB Tablet outside hospitals for last month (Ubist) announced the day before was 9.89 billion KRW. The cumulative total from January to October this year reached 88 billion KRW, already surpassing last year's total performance of 76.1 billion KRW. HK Innoen recently expanded the insurance coverage of K-CAB to include gastric ulcers and newly developed an orally disintegrating tablet, focusing on strengthening its position as a blockbuster domestic new drug.

K-CAB Tablet is the 30th new drug independently developed in Korea in 2019. It surpassed 100 billion KRW in cumulative sales in less than two years and has achieved a cumulative prescription performance of 195 billion KRW since its launch. K-CAB Tablet was developed as a new P-CAB class product, showing faster efficacy compared to existing PPI class products and can be taken regardless of before or after meals. It also has the special advantage of excellent sustained efficacy that suppresses nighttime gastric acid secretion.

Additionally, HK Innoen recently applied to the Ministry of Food and Drug Safety for approval of the orally disintegrating tablet formulation, which dissolves in the mouth, following the tablet form. Orally disintegrating tablets are mainly used for patients who have difficulty swallowing pills or cannot drink water. The company expects that once the orally disintegrating tablet is officially launched in the first half of next year, the scope of K-CAB's market entry will expand further.

Seokhee Kang, CEO of HK Innoen, said, "K-CAB Tablet is scheduled to actively enter overseas markets such as China starting next year," adding, "We will further strengthen the market position of the blockbuster new drug K-CAB through research on expanded indications, differentiated clinical trials, and development of various formulations."